Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 11, 2022
At journal club this week, a question that impacts all intensivists - when patients with septic shock need ongoing resuscitation after their initial 30cc/kg treatment, what strategy for intravenous fluid volume should we use?
Find out in thread👇 pic.twitter.com/z0pMmEp732
After CHIP we discussed CHAP. In case you missed it, we have you covered here:
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) June 1, 2022
✳️ Last week's #NephJC in 10 tweets ✳️
Did you miss the latest CHAPter of #NephJC? Join us as we catch you up on the Chronic Hypertension in Pregnancy trial -- the CHAP chat!https://t.co/zdjwgONpt1 pic.twitter.com/4RK5HKulC6
With guidelines as big as the latest ISPD whopper you can’t #TenTweetNephJC it - but check out the alternative NephJC summary tweetorial with some take home points below.
Wrapping up this chapter of #NephJC with a tweetorial 🧵of take home messages on PD peritonitis, after two great chats regarding the ISPD peritonitis guideline update👇https://t.co/VieQSo0b5C
— Nephrology Jrnl Club (@NephJC) May 2, 2022
Third instalment of our NephJC summary tweetorials - catch it at the link to learn more about the trade-offs in timing when best to start dialysis in progressive CKD.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) February 16, 2022
✳️ 10 tweets to catch-up on the most recent #NephJC ✳️
This week - when is the ideal time to start dialysis in progressive chronic kidney disease?
Later starts lower the burden on patients & use of healthcare resources, but what’s the trade-off? pic.twitter.com/CG2YavjzEQ
